This case illustrates several scientific and practical points related to the diagnosis, localization, and management of pheochromocytoma. First, the finding of a high plasma level of free ...

In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

adrenal incidentalomas have become an important clinical entity for which pheochromocytoma must be considered, regardless of signs and symptoms. Third, knowledge of the relationship between ...

Most patients with pheochromocytoma have high blood pressure. Many patients have three main symptoms: headache, excess sweating and episodes of a hard, fast heartbeat (palpitations). You should talk ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

A pheochromocytoma is a type of tumor found in the adrenal glands or certain nerve cells. These tumors are very rare but can cause dramatic symptoms because they tend to secrete large amounts of ...

Virtually all patients with MEN2B develop MTC and roughly half develop pheochromocytoma. Successful management of these patients is highly dependent on early diagnosis and treatment of these often ...

Pheochromocytoma is a very rare disease with an extremely ... although CT scan is the preferred imaging modality for diagnosis.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.